



ASX & MEDIA RELEASE

10 OCTOBER 2019

DEFINITIVE COMMERCIAL AGREEMENT EXECUTED TO EXPAND NUTRACEUTICAL BUSINESS IN THE USA

- Definitive Commercial Agreement executed with American Nutritional Corp Inc (ANC) to expand Medlab's nutraceutical business in the USA
- First revenues are expected early 2020

Further to the ASX announcement made on 5 August 2019 regarding the execution of the Heads of Agreement with ANC, Medlab Clinical Ltd (ASX: MDC) is pleased to announce that it has executed a definitive commercial agreement with ANC for a US market entry using MDC's existing nutraceuticals.

ANC is a US entity with audited and approved manufacturing capabilities for several large, institutional US brands.

Commercial terms have now been finalised on a collaborative agreement with ANC having distribution and manufacturing rights of MDC's nutraceutical products in the USA. The US dietary supplements market was valued at \$124.8B USD in 2018 with a CAGR of 6.4%.

Through MDC's strong research and extensive patent portfolio, the nutraceutical range is well positioned for ANC clients. The deal will see MDC products enter both the medical and consumer markets through healthcare practitioners, pharmacies and health food stores through larger, existing companies already strong in branding and distribution. Whilst Medlab will be featured on the label, the overall intent is to rebrand to suit the clients general branding strategy.

Secondary to this, the agreement also provides a significant opportunity to expand the relationship with ANC and capitalise on their manufacturing capabilities, providing ongoing economies of scale for the local market.

The official launch of the 1st Brand will occur at a major US medical conference, the 27th Annual World Congress, in December, run by the American Academy of Anti-Aging Medicine (A4M).

Medlab CEO, Dr Sean Hall said "this agreement provides a great opportunity to expand the commercialisation opportunities for Medlab into such a large market like the USA. Having access to clients of this calibre and being able to tap into their supply chains is very exciting and is a further example of the appeal of our patents research and strong clinical capabilities."

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: DR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.